SCHEMBL7206601

SCHEMBL7206601

CCCC(=O)NCC1=Cc2c(ccc3c2OCCO3)OC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 7/20 0.56
MTNR1B P49286 4/20 0.43
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 4/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7962738 0.85 MTNR1A (0.54) MTNR1AMTNR1BALDH1A1NPSR1KDM4E
SCHEMBL6077525 0.75 MTNR1A (0.73) MTNR1AMTNR1BKMT2AL3MBTL1CYP3A4
SCHEMBL7201190 0.73 ITGB2 (0.33) MTNR1AMTNR1BALDH1A1SMN1; SMN2KDM4E
SCHEMBL5225146 0.72 MTNR1A (1.00) MTNR1AMTNR1BTP53HTTKMT2A
SCHEMBL7019321 0.70 MTNR1A (0.80) MTNR1AHTTKMT2AGAAMEN1
SCHEMBL7199997 0.70 ITGB2 (0.33) SMN1; SMN2HTTLMNA
SCHEMBL7201840 0.70 ITGB2 (0.33) SMN1; SMN2HTTLMNA
SCHEMBL7204127 0.69 MTNR1A (0.77) MTNR1AMTNR1B
SCHEMBL6076181 0.68 MTNR1A (0.62) MTNR1ASMN1; SMN2TP53KMT2AMAPK1
SCHEMBL7520573 0.65 MTNR1A (0.73) MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 MTNR1A 1/4885MTNR1B 2/4885ALDH1A1 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.